Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Exelixis, Inc. - Common Stock
(NQ:
EXEL
)
44.36
-0.01 (-0.02%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
July 28, 2025
From
Exelixis, Inc.
Via
Business Wire
EXELIXIS INC (NASDAQ:EXEL): A Prime Example of Affordable Growth in Biotech
↗
July 28, 2025
EXELIXIS (NASDAQ:EXEL) offers strong growth, fair valuation, and financial health, fitting the "Affordable Growth" strategy with high scores in profitability and low bankruptcy risk.
Via
Chartmill
Topics
Bankruptcy
Uncovering Potential: Exelixis's Earnings Preview
↗
July 25, 2025
Via
Benzinga
EXELIXIS INC (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Breakout Potential
↗
July 25, 2025
EXELIXIS INC (EXEL) combines strong growth fundamentals—high profitability, solid financials, and rising revenue—with bullish technical signals, making it a promising breakout candidate for investors.
Via
Chartmill
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
July 24, 2025
From
Exelixis, Inc.
Via
Business Wire
Earnings Scheduled For July 28, 2025
↗
July 28, 2025
Via
Benzinga
Peering Into Exelixis's Recent Short Interest
↗
July 22, 2025
Via
Benzinga
Peering Into Exelixis's Recent Short Interest
↗
July 04, 2025
Via
Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A High-Growth Momentum Stock with Strong Technical Setup
↗
July 22, 2025
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors and breakout traders.
Via
Chartmill
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
↗
July 20, 2025
Via
The Motley Fool
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in High-Growth Oncology Stocks
↗
July 19, 2025
EXELIXIS (NASDAQ:EXEL) shows strong technical and fundamental growth, meeting Minervini’s Trend Template criteria with high earnings momentum and a bullish chart setup.
Via
Chartmill
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
↗
July 19, 2025
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.
Via
The Motley Fool
Topics
Intellectual Property
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
July 14, 2025
From
Exelixis, Inc.
Via
Business Wire
Assessing Exelixis: Insights From 12 Financial Analysts
↗
July 10, 2025
Via
Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors
↗
July 08, 2025
EXELIXIS INC (NASDAQ:EXEL) shows strong growth, profitability, and financial health, making it a standout for investors following Louis Navellier’s strategy. With high earnings surprises and...
Via
Chartmill
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation
↗
July 05, 2025
EXELIXIS INC (NASDAQ:EXEL) offers strong growth potential at a reasonable valuation, backed by solid profitability and a debt-free balance sheet. A compelling pick for growth investors.
Via
Chartmill
2 Stocks to Buy With Less Than $50
↗
July 04, 2025
Via
The Motley Fool
Topics
Intellectual Property
EXELIXIS INC (NASDAQ:EXEL) - An Undervalued Biotech Stock With Strong Fundamentals
↗
July 02, 2025
EXELIXIS (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, zero debt, and robust growth prospects, making it a candidate for value investors.
Via
Chartmill
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Technical Breakout Potential
↗
June 30, 2025
EXELIXIS (NASDAQ:EXEL) is a strong growth stock with breakout potential, backed by robust earnings, revenue growth, and a healthy technical setup.
Via
Chartmill
3 No-Brainer Stocks to Buy for Under $100 Right Now
↗
June 28, 2025
Via
The Motley Fool
Topics
Intellectual Property
EXELIXIS INC (NASDAQ:EXEL) – A High Growth Momentum Stock with Strong Technical Setup
↗
June 28, 2025
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors. The stock is consolidating with clear support...
Via
Chartmill
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
↗
June 24, 2025
Via
Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Growth and Momentum Investing
↗
June 24, 2025
EXELIXIS INC (NASDAQ:EXEL) shows strong growth momentum and meets Minervini’s trend criteria, making it a stock to watch for high-growth investors.
Via
Chartmill
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug
↗
June 23, 2025
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug.
Via
Investor's Business Daily
Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday
↗
June 23, 2025
Via
Benzinga
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars
↗
June 23, 2025
Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported.
Via
Benzinga
AMD To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday
↗
June 23, 2025
Via
Benzinga
Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug
↗
June 23, 2025
Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study.
Via
Investor's Business Daily
What 9 Analyst Ratings Have To Say About Exelixis
↗
June 23, 2025
Via
Benzinga
These stocks are moving in today's pre-market session
↗
June 23, 2025
Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today